Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction
Selvaraj S, Patel S, Sauer A, McGarrah R, Jones P, Kwee L, Windsor S, Ilkayeva O, Muehlbauer M, Newgard C, Borlaug B, Kitzman D, Shah S, Margulies K, Husain M, Inzucchi S, McGuire D, Lanfear D, Javaheri A, Umpierrez G, Mentz R, Sharma K, Kosiborod M, Shah S. Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction. Circulation Heart Failure 2024, 17: e011980. PMID: 39421941, PMCID: PMC11634023, DOI: 10.1161/circheartfailure.124.011980.Peer-Reviewed Original ResearchMeSH KeywordsAgedBenzhydryl CompoundsBiomarkersClinical Trials, Phase IV as TopicFatty AcidsFemaleGlucosidesHeart FailureHumansMaleMetabolomicsMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicSodium-Glucose Transporter 2 InhibitorsStroke VolumeTreatment OutcomeVentricular Function, LeftConceptsHeart failureBranched-chain amino acidsEnd pointsEjection fractionLeft ventricular ejection fraction spectrumMetabolite factorsMetabolic effectsSpectrum of ejection fractionSGLT2 inhibitor dapagliflozinReduced ejection fractionHF-related outcomesEjection fraction spectrumMechanisms of benefitDEFINE-HFAcid metabolismInhibitor dapagliflozinOverall cohortMetabolomic profilesLVEFMetabolic signaturesRandomized trialsDapagliflozinHF subtypesFatty acid metabolismAmino acid metabolismCardiac And Kidney Benefits Of Dapagliflozin Are Associated With ApoM Levels In Patients With Heart Failure With Reduced Ejection Fraction
Chang J, Javaheri A, Sauer A, Windsor S, Fu Z, Jones P, Margulies K, Lanfear D, Nassif M, Husain M, Inzucchi S, McGuire D, Pitt B, Scirica B, Kosiborod M. Cardiac And Kidney Benefits Of Dapagliflozin Are Associated With ApoM Levels In Patients With Heart Failure With Reduced Ejection Fraction. Journal Of Cardiac Failure 2024, 30: 236. DOI: 10.1016/j.cardfail.2023.10.284.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2 inhibitorsUrine albumin-creatinine ratioLog-transformed NT-proBNPLog-transformed NT-proBNP levelsDapagliflozin-treated patientsNT-proBNP levelsReduced ejection fractionNT-proBNPHeart failureApoM levelsEjection fractionType 2 diabetes mellitusPlacebo-treated patientsAlbumin-creatinine ratioCotransporter 2 inhibitorsEffect of dapagliflozinMultivariable linear regressionSphingosine-1-PhosphateKidney benefitsSGLT2i dapagliflozinDapagliflozin groupHF trialsPlacebo groupDapagliflozin treatmentOverall cohort
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply